Category: Wall Street Beat
QMed releases a list of the 5 worst-performing medical device companies of early 2014, including Siemens, GE and Fresenius, among others.
MASSDEVICE ON CALL — Medtech giants have seen Wall Street bumps so far this year, but several of the company's in the industry's top 40 haven't been so fortunate.
Device maker TriVascular Technologies plans an IPO in hopes of raising as much as $100 million to repay Boston Scientific, build up sales & marketing and fund additional R&D.
California medical device maker TriVascular Technologies is looking to raise as much as $100 million through its initial public offering, the details of which have yet to be finalized.
British medical device maker Lombard Medical says it could raise as much as $80 million in its U.S. initial public offering.
Lombard Medical Technologies (LON:LMT) said yesterday that it could raise up to $80 million in its debut on the U.S. stock market.
Analogic is on track with layoffs and facilities closures announced last year, but ALOG shares dive after the company reports disappointing earnings for its 2nd quarter and projects flat progress for the year ahead.
Biomet's private equity owners announce plans to take the orthopedics giant back on the public market.
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.
A group of private PE players including the Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts and TPG acquired Biomet for $11.4 billion in 2007, placing medtech veteran Jeffrey Binder at the helm.
Medical risk-assessment tools maker Semler Scientific raises $10 million, meeting a lowered projection for its initial public offering.
Oregon-based Semler Scientific (NSDQ:SMLR) closed its initial public offering with just over $10 million raised.
Sleep apnea treatment company ResMed approves a buyback of up to 20 million shares of its common stock on an ongoing basis.
ResMed's (NYSE:RMD) board of directors authorized a new share buyback program granting the company approval to reclaim up to 20 million shares of its common stock on the open market.